Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that regularly issues updates on its cardiac monitoring platform, regulatory milestones, and commercialization plans. Company news highlights its focus on transforming cardiac care through portable, cable-free ECG technologies that can be used by adult patients in clinical settings or at home for arrhythmia assessment.
News releases frequently cover developments related to HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software. These include FDA 510(k) clearance for arrhythmia assessment, the regulatory path for the 12-lead synthesis software, and the company’s responses to a Not Substantially Equivalent (NSE) decision and subsequent successful appeal. Investors can also find updates on clinical studies such as the VALID-ECG study and deep learning research presented at conferences like HRX Live, which examine how HeartBeam’s algorithms perform in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
HeartBeam’s news flow also addresses commercial readiness, including plans for limited U.S. launch with concierge and preventive cardiology practices, establishment of a cardiology reader service, and infrastructure for customer service, contract manufacturing, and logistics. Announcements about the partnership with HeartNexus, Inc. describe how synthesized 12-lead ECGs from HeartBeam’s system will be reviewed by a network of board-certified cardiologists, supporting arrhythmia assessment and patient triage outside traditional healthcare facilities.
In addition, periodic earnings releases and conference participation notices provide insight into the company’s operating expenses, cash position, and engagement with investors and industry partners. Visitors to this news page can review these updates to understand how HeartBeam is progressing on regulatory, clinical, and commercialization objectives for its cardiac monitoring technologies.
HeartBeam, Inc. (NASDAQ: BEAT) has submitted a 510(k) application to the US FDA for its HeartBeam AIMI™ technology, aimed at improving heart attack diagnosis. This step is crucial for the company's commercialization efforts within a $500 million market. With over 18 million individuals affected by coronary artery disease in the US, and heart attacks occurring every 40 seconds, the technology aims to enhance the diagnostic process in emergency departments. CEO Branislav Vajdic expressed optimism regarding FDA clearance and anticipated a full commercial roll-out in Q1 2023.
HeartBeam, Inc. (NASDAQ: BEAT) reported its Q2 2022 financial and operational results, highlighting significant advancements towards FDA submissions for its HeartBeam AIMI™ software platform and AIMIGo™ telehealth solution. The company plans to submit the AIMI platform for FDA clearance around August 15, 2022, and aims for AIMIGo submission in Q4 2022. Q2 net loss was $3.5 million, with cash reserves at $9.3 million. HeartBeam expanded its target patient population by including unstable angina, enhancing the platform's clinical validation study scope.
HeartBeam, Inc. (NASDAQ: BEAT) announced the appointment of Ken Persen as Chief Technology Officer, bringing over 25 years of experience in digital healthcare and cardiac devices. Persen will lead the technology strategy and development of the HeartBeam AIMI™ and AIMIGo™ platforms, enhancing the company's innovative ECG telemedicine technology. This appointment aims to improve the management of heart attack symptoms outside medical institutions, addressing a significant market need.
Summary not available.
HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on August 11, 2022 at 4:30 p.m. Eastern Time to discuss its second quarter results, which ended June 30, 2022. The call will also cover recent announcements and key milestones for 2022. CEO Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will present and facilitate a Q&A session. Investors can access the call via dial-in or webcast. A replay will be available after the call until November 11, 2022.
HeartBeam, Inc. (NASDAQ: BEAT) announced an expansion of its clinical validation study to include a broader patient population for its emergency department software technology. The decision follows the recent AHA guidelines and aims to include unstable angina patients, which may enhance heart attack detection. HeartBeam plans to file a 510K submission by August 15, 2022, which remains unaffected by the Telehealth product's timeline, scheduled for Q4 2022. This expanded scope aligns with their goal of improving cardiovascular diagnosis.
HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare innovator, will present at the LD Micro Invitational XII Conference from June 7-9, 2022, in Westlake Village, CA. CFO Rick Brounstein and CBO Jon Hunt, PhD, will host 25-minute meetings and deliver a presentation on June 7 at 4:00 pm ET. HeartBeam specializes in proprietary ECG telemedicine technology aimed at improving heart attack detection outside medical institutions. This significant advancement addresses the high-risk cardiovascular patient population's needs. For more details, visit ir.heartbeam.com.
HeartBeam, Inc. (NASDAQ: BEAT) will participate virtually in the H.C. Wainwright Global Investment Conference from May 23 – 26, 2022.
The company's CEO, Branislav Vajdic, CFO Rick Brounstein, and CBO Jon Hunt will conduct one-on-one meetings during the event. Jon Hunt will also deliver a virtual presentation available on-demand starting May 24, 2022.
This innovative digital healthcare company focuses on ECG telemedicine technology for heart attack detection, providing significant advancements in diagnosing cardiovascular diseases outside medical institutions.
HeartBeam, a digital healthcare company (NASDAQ: BEAT), reported its Q1 2022 results, highlighting a net loss of $2.1 million, up from $210,000 in Q1 2021. R&D expenses increased significantly to $734,000, compared to $29,000 in the prior year. The company remains on track for an FDA submission for its Emergency Department Myocardial Infarction software in Q2 2022 and a Telehealth solution in Q4 2022. With cash reserves of $11.2 million, HeartBeam anticipates a full commercial rollout of its ED Software Tool in Q1 2023.
The acquisition of RedCrow by Alira Health aims to enhance access to alternative investments in healthcare startups. Founded in 2016, RedCrow has raised $250 million through over 250 fundraises. This strategic move allows Alira to extend its patient engagement mission by involving them in the financing of new healthcare solutions. The financial terms of the acquisition remain undisclosed, but the collaboration is expected to democratize healthcare investing, promoting innovation in early-stage pharma and MedTech.